Maravai Lifesciences Holdings (MRVI) Goodwill & Intangibles (2020 - 2026)
Maravai Lifesciences Holdings' (MRVI) quarterly Goodwill & Intangibles came in at $274.3 million in Q1 2026, up 35.14% year-on-year from $203.0 million in Q1 2025, and down 2.37% quarter-over-quarter from $281.0 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Goodwill & Intangibles (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Goodwill & Intangibles history runs 7 years deep, the most recent figure standing at $274.3 million for Q1 2026.
- On a quarterly basis, Goodwill & Intangibles rose 35.14% year-over-year to $274.3 million in Q1 2026; TTM through Mar 2026 was $274.3 million, a 35.14% increase from a year earlier, with the FY2025 full-year figure at $281.0 million, down 20.82% from the prior year.
- Goodwill & Intangibles fell to $274.3 million in Q1 2026 per MRVI's latest filing, from $281.0 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $561.2 million in Q2 2023 and bottomed at $203.0 million in Q1 2025.
- The 5-year median for Goodwill & Intangibles is $373.6 million (2024), against an average of $411.3 million.
- Across the five-year window, Goodwill & Intangibles surged 85.09% in 2022 and sank 62.42% in 2025, its largest moves.
- Year by year, Goodwill & Intangibles stood at $500.4 million in 2022, then climbed by 9.32% to $547.0 million in 2023, then plunged by 35.13% to $354.8 million in 2024, then retreated by 20.82% to $281.0 million in 2025, then declined by 2.37% to $274.3 million in 2026.
- Per Business Quant, the three latest MRVI Goodwill & Intangibles figures stand at $274.3 million (Q1 2026), $281.0 million (Q4 2025), and $315.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn |
| 10 | Maravai Lifesciences Holdings | 992.04 Mn | 826.11 Mn | 33.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 274.32 Mn |
| Dec 31, 2025 | 280.97 Mn |
| Sep 30, 2025 | 315.31 Mn |
| Jun 30, 2025 | 322.50 Mn |
| Mar 31, 2025 | 202.98 Mn |
| Dec 31, 2024 | 354.84 Mn |
| Sep 30, 2024 | 373.65 Mn |
| Jun 30, 2024 | 533.28 Mn |
| Mar 31, 2024 | 540.15 Mn |
| Dec 31, 2023 | 547.02 Mn |
| Sep 30, 2023 | 553.89 Mn |
| Jun 30, 2023 | 561.23 Mn |
| Mar 31, 2023 | 358.27 Mn |
| Dec 31, 2022 | 500.36 Mn |
| Sep 30, 2022 | 506.43 Mn |
| Jun 30, 2022 | 512.65 Mn |
| Mar 31, 2022 | 254.20 Mn |
| Dec 31, 2021 | 270.34 Mn |
| Sep 30, 2021 | 274.03 Mn |
| Jun 30, 2021 | 277.88 Mn |